11th May 2020 Content supplied by: AMS Biotechnology (Europe) Limited
Identifying Targets for Development of COVID-19 Drugs & Vaccines
AMSBIO has extended its COVID-19 research portfolio with the introduction of a service to provide custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 to help researchers identify potential targets for the development of therapeutic drugs and vaccines.
Various research groups around the world have demonstrated that SARS-CoV-2 uses its spike glycoprotein S, the main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry.
In response to widespread demand, AMSBIO has developed a custom service to provide ready-to-use in vitro and in vivo grade lentiviral particles pseudotyped with coronavirus S protein.
Pseudotyping of lentivirus is available with wild type or mutant S proteins from a wide range of coronavirus species. In addition, AMSBIO can offer wide-ranging customization options including the addition of reporter genes for monitoring viral entry. This complete range of products are safe to be used in BSL-2 labs.
The AMSBIO lentiviral system is a novel gene delivery tool using lentivectors for gene expression or knockdown. Lentivirus can effectively transduce both dividing and non-dividing mammalian cells, and integrate into the host genome, allowing stable long-term, high-level gene expression both in vivo and in vitro. Unlike traditional retroviral system, AMSBIO lentivirus is much more actively imported into the nuclei of non-dividing cells and stably integrated into the host cell's genome independent of cell cycle.
For further information on custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 and other tools for Coronavirus research please visit www.amsbio.com/coronavirus.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / or use the 'Request Information' button provided below.
Date Published: 11th May 2020
Source article link: View